Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 12/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.55 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.55 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123147 | 1.00 | PDE10A (0.64) | PDE10ACYP1A2CYSLTR2CYSLTR1LGALS3 | |
| SCHEMBL3271852 | 0.81 | PDE10A (0.62) | PDE10ACYP1A2CYSLTR2CYSLTR1LGALS3 | |
| SCHEMBL30123158 | 0.81 | PDE10A (0.62) | PDE10ACYP1A2CYSLTR2CYSLTR1LGALS3 | |
| SCHEMBL30122850 | 0.81 | PDE10A (0.71) | PDE10ACYP1A2CYSLTR2CYSLTR1LGALS3 | |
| SCHEMBL3270070 | 0.81 | PDE10A (0.71) | PDE10ACYP1A2CYSLTR2CYSLTR1LGALS3 | |
| SCHEMBL3269684 | 0.81 | PDE10A (0.67) | PDE10ACYP1A2CYSLTR2CYSLTR1LGALS3 | |
| SCHEMBL30123685 | 0.81 | PDE10A (0.67) | PDE10ACYP1A2CYSLTR2CYSLTR1LGALS3 | |
| SCHEMBL3270047 | 0.80 | F2 (0.47) | CYP1A2 | |
| SCHEMBL3271388 | 0.79 | PDE10A (0.62) | PDE10ACYP1A2CYSLTR2CYSLTR1LGALS3 | |
| SCHEMBL4763336 | 0.79 | RAB9A (0.57) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102491969-A | Heteroaromatic quinoline compounds | PFIZER PROD INC | 2012-06-13 | — | — | CN | claimed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | claimed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | claimed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | claimed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | claimed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | claimed |
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| US-10039764-B2 | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression | UNIVERSITY OF SOUTH ALABAMA (US) | 2018-08-07 | — | — | US | disclosed |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2015006689-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2675456-A1 | METHODS FOR TREATING DISEASES OF THE RETINA | Allergan, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7825254-B2 | Heteroaromatic quinoline compounds | PFIZER INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | disclosed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039764-B2 | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression | PDE4A, PDE7B, PDE2A | PDE10A 12/4885CYP1A2 2732/4885CYSLTR2 2749/4885 |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PDE12, PDE7A, PDE4A | PDE10A 8/4885CYP1A2 40/4885CYSLTR2 2451/4885 |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | PDE10A 5/4885CYP1A2 1890/4885CYSLTR2 341/4885 |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PDE12, PDE7A, PDE4A | PDE10A 8/4885CYP1A2 40/4885CYSLTR2 2451/4885 |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | PDE4A, PDE7B, PDE2A | PDE10A 12/4885CYP1A2 2732/4885CYSLTR2 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.